With Dr. Clay Siegall as CEO of Seattle Genetics the company is becoming a major name in the pharmaceutical and biotechnology industry. Dr. Clay Siegall first began his career at George Washington University where he received a pH.D. in Genetics. In 1988 he accepted a position as a Staff Fellow at the National Cancer Institute, National Institutes of Health. There he continued on as a Biotechnology Fellow until 1991.
He furthered his career at the Bristol-Myers Squibb Pharmaceutical Research Institute where he worked as a Senior Research Investigator and was later promoted to the position of Principal Scientist. It was in 1998 that Dr. Clay Siegall co-founded Seattle Genetics; a biotechnology company that develops antibody-based cancer treatments and therapies. His background in genetics, cancer research, and therapeutic drug development has made Dr. Clay Siegall an invaluable member of management at Seattle Genetics.With his leadership and direction Seattle Genetics has grown to have an enterprise value of $4.7 billion.
His entrepreneural success has been recognized with the 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year award.Today Seattle Genetics current focus is on developing antibody-drug conjugates (ADCs). ADCs are an attractive cancer treatment as the therapy can discriminate between healthy and diseased tissue, enabling ADCs to deliver cancer-killing drugs directly to the cancerous tissue. Seattle Genetics most recently FDA approved product, ADCETRIS ( brentuximab bedroom), is now globally available and is sold in over 60 countries. By developing a new class of ADCs Seattle Genetics hopes to become the foundation of treatment for cancers including lymphoma and leukemia.